When stopping GLP-1 drugs like Ozempic, hunger doesn't just return to normal; it comes back with a "ferocious, animalistic" vengeance that is far more intense than before starting the medication. This powerful rebound effect is a primary driver of rapid weight regain.

Eli Lilly and Novo Nordisk's DTC programs for weight loss drugs give employers an alternative to point employees towards, providing cover to drop expensive insurance coverage and potentially reducing access for patients who rely on it.

Offering 12-month upfront subscriptions for weight-loss drugs creates a psychological 'sunk cost' for patients. This may compel them to continue using a medication despite adverse side effects or having already achieved their health goals, simply to 'get their money's worth,' potentially leading to negative health outcomes.

Widespread, subsidized distribution of GLP-1s to combat obesity could drastically cut national healthcare expenditures. Since a large portion of medical costs are linked to obesity, this health intervention could reduce the budget deficit more effectively than many economic policies.

Despite showing massive weight loss, new obesity drugs from Eli Lilly and others have high discontinuation rates due to side effects. This suggests the industry's singular focus on efficacy may be hitting diminishing returns, opening a new competitive front based on better patient tolerance and adherence.

While GLP-1 drugs can jumpstart weight loss by reducing appetite, they don't address poor food quality. If users simply eat less ultra-processed food, they risk severe protein and micronutrient deficiencies, leading to different long-term health consequences.

The conversation frames GLP-1 weight-loss drugs not merely as a healthcare breakthrough but as a potential moonshot for the national economy. A mass government rollout could drastically reduce healthcare costs, improve mental health, and boost productivity, representing a powerful tool for social and economic policy with far-reaching ramifications.

Treating obesity with drugs like Wegovy for a limited time, such as two years, is akin to only treating high cholesterol temporarily. This policy ignores the medical reality that obesity is a chronic disease requiring lifelong management, not a short-term condition.

By negotiating the price of weight-loss drugs from $1,200 down to ~$200, the administration expects a net positive ROI for the government within two years. The savings from preventing obesity-related chronic illnesses will outweigh the drug costs.